ArticleArchives of gynecology and obstetrics2025
Clinical routine care for choriocarcinoma: a descriptive analysis of data from the Baden-Wuerttemberg Cancer Registry (BWCR).
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Choriocarcinoma: Navigating risk, resistance, and remarkable curability.Case reports in women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChoriocarcinoma is a rare tumour. In Germany, due to its low incidence and lack of centralisation in care, only limited data are available on real-world clinical practice. This study aims to analyse tumour characteristics, treatment, and outcomes of patients with gestational choriocarcinoma using data from the Baden-Wuerttemberg Cancer Registry (BWCR), Germany.
methodsWe included patients aged 18-50 years diagnosed with choriocarcinoma between 2015 and 2023, reported to the BWCR. The cases were identified using ICD-O-3 codes 9100/3, 9101/3 and ICD-10-GM code C58.9. Diagnostic and treatment information was derived from standardised registry entries and pathology reports. First-line treatment was defined as therapy initiated within 120 days of diagnosis. Data were analysed using descriptive statistics.
results38 patients (mean age 33.4 years) were included; 39% presented with metastatic disease, predominantly isolated lung metastases (67%). Systemic therapy was reported in 28 cases: MTX (n = 10), EMA-CO (n = 12), and - due to timecourse or substance - other regimens (n = 6). The reported treatment duration ranged from 20 - 120 days (MTX) and 50 -154 days (EMA-CO). One MTX-treated patient (10%) required escalation to EMA-CO. Among EMA-CO cases, therapy was discontinued in three patients and one second-line treatment reported. The reported adverse events were in line with published data.
conclusionThis population-based analysis provides real-world insights into choriocarcinoma care in Baden-Wuerttemberg. While outcomes align with current guidelines, observed resistance to MTX and EMA-CO highlights the need for individualised treatment and closer monitoring. These findings underline the value of registry data in guiding therapy optimization-even in rare diseases like choriocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.